PUBLIC COMPANY
save$BOLDBoundless Bio, Inc.
$BOLDSan Diego, CA, USupdated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
- phase1Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
- phase1Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
🐶 Hiring Signal
News
- Novartis projects slowed growth, pins hopes on billions in pipeline potentialWith Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.biospace · 3h ago
- Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drugThe go-ahead for Alnylam Pharmaceuticals–partnered Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.biospace · 4h ago
- Sanders’ ‘Medicare for All’ plan accrues more liberal and moderate support in CongressSen. Bernie Sanders pushed back on assumptions that Trump would veto an expanded Medicare plan. “I am not absolutely certain that Trump would not sign it,” he said.stat · 6h ago
- Why 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London eventPanelists at Fierce Biotech's London Life Sciences Week event discussed whether Europe can pull its weight in biopharma investment next year against the gravitational pull of the U.S. and China.fiercebiotech · 2d ago
- Opinion: Medical school should start after students take the Step 1 exam“It’s time for a radical reimagining of medical education,” write Rachel Fabi and Amy Caruso Brown.stat · 3d ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificJohnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.fiercebiotech · 3d ago
- HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s DayIbogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.biospace · 6d ago
- Without US action on China’s innovation blitz, biotech leaders see a Rust Belt futurePolicy uncertainty is hampering the growth of U.S. biotech as China rises thanks to carefully planned investment in the industry, experts said during a BioSpace webinar.biospace · 8d ago
- STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drugIonis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug.stat · 9d ago
- STAT+: Bill Ackman’s bold plan to transform brain researchBillionaire Bill Ackman as a bold plan to transform brain research, spurred by a tragic backstory.stat · 10d ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that